Table 3.
Complications, Treatments, and Prognosis of Patients with Corona Virus Disease 2019 (COVID-19).
| Patients (n = 200) | ICU(n = 29) | Non-ICU(n = 171) | P value | |
|---|---|---|---|---|
| Complications | ||||
| ARDS | 32 (16 %) | 21 (72.4 %) | 11 (6.4 %) | 0.00 |
| Acute cardiac injury | 20 (10 %) | 15 (51.7 %) | 5 (2.9 %) | 0.00 |
| Acute kidney injury | 24 (12 %) | 12 (41.3 %) | 12 (7.0 %) | 0.00 |
| Secondary infection | 12 (6.0) | 5 (17.2 %) | 7 (4.1 %) | 0.00 |
| Shock | 4 (2%) | 4 (13.8 %) | 0 | 0.00 |
| Treatment | ||||
| Antiviral therapy | 199 (99.5 %) | 28 (96.6 %) | 171 (100 %) | 0.01 |
| Antibiotic therapy | 141 (70.5 %) | 29 (100 %) | 112 (65.5 %) | 0.00 |
| Use of corticosteroid | 112 (56 %) | 20 (69.0 %) | 92 (53.8 %) | 0.12 |
| CRRT | 2 (1%) | 2 (6.9 %) | 0 | 0.00 |
| Oxygen support | ||||
| Nasal cannula | 158 (79 %) | 5(17.2 %) | 153 (89.5 %) | 0.00 |
| Non-invasive ventilation or high-flow nasal cannula | 35 (17.5 %) | 24 (82.8 %) | 11 (6.4 %) | 0.00 |
| Invasive mechanical ventilation |
16 (8.0 %) | 14 (48.3 %) | 2 (1.2 %) | 0.00 |
| Prognosis | ||||
| Hospitalization | 143 (71.5 %) | 11 (37.9 %) | 132 (77.2 %) | 0.00 |
| Discharge | 42 (21 %) | 4 (13.8 %) | 38 (22.2 %) | 0.94 |
| Death | 15 (7.5 %) | 14 (48.3 %) | 1 (0.6 %) | 0.00 |